Trial Profile
Randomized Phase II Study Comparing 5FU/LV+Nal-IRI, Gemcitabine+Nab-paclitaxel or a Sequential Regimen of 2 Months 5FU/LV+Nal-IRI Followed by Two Months of Gemcitabine+Nab-paclitaxel, in Metastatic Pancreatic Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Feb 2024
Price :
$35
*
At a glance
- Drugs Fluorouracil (Primary) ; Folinic acid (Primary) ; Irinotecan (Primary) ; Gemcitabine; Levofolinic acid; Paclitaxel
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- Acronyms FUNGEMAX
- 29 Jan 2024 Status changed from recruiting to active, no longer recruiting.
- 16 Aug 2023 Planned primary completion date changed from 1 Dec 2022 to 1 Jun 2024.
- 20 Nov 2018 Status changed from not yet recruiting to recruiting.